Geode Capital Management LLC Purchases 21,220 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Geode Capital Management LLC raised its position in Myriad Genetics, Inc. (NASDAQ:MYGN) by 1.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,154,035 shares of the company’s stock after buying an additional 21,220 shares during the quarter. Geode Capital Management LLC owned about 2.37% of Myriad Genetics worth $59,010,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in MYGN. State Street Corp raised its position in shares of Myriad Genetics by 8.3% in the third quarter. State Street Corp now owns 4,703,442 shares of the company’s stock valued at $128,827,000 after purchasing an additional 359,685 shares during the period. Earnest Partners LLC raised its holdings in Myriad Genetics by 3.5% during the 2nd quarter. Earnest Partners LLC now owns 4,072,018 shares of the company’s stock valued at $99,602,000 after acquiring an additional 138,960 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Myriad Genetics by 2.8% during the second quarter. Dimensional Fund Advisors LP now owns 2,776,959 shares of the company’s stock worth $67,924,000 after acquiring an additional 75,445 shares in the last quarter. Disciplined Growth Investors Inc. MN grew its position in shares of Myriad Genetics by 21.1% in the third quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company’s stock valued at $69,226,000 after purchasing an additional 440,107 shares in the last quarter. Finally, Sei Investments Co. raised its stake in shares of Myriad Genetics by 5.4% during the 2nd quarter. Sei Investments Co. now owns 2,417,192 shares of the company’s stock valued at $59,125,000 after purchasing an additional 124,007 shares during the period. Hedge funds and other institutional investors own 99.02% of the company’s stock.

Wall Street Analyst Weigh In

MYGN has been the subject of several analyst reports. StockNews.com downgraded Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Morgan Stanley lowered their target price on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Monday, November 18th. Bank of America reduced their price target on shares of Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating for the company in a research report on Friday, December 13th. Leerink Partnrs downgraded Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th. Finally, UBS Group began coverage on Myriad Genetics in a research note on Tuesday, December 10th. They issued a “neutral” rating and a $18.00 target price on the stock. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Myriad Genetics presently has a consensus rating of “Hold” and an average price target of $24.27.

Myriad Genetics Stock Performance

NASDAQ:MYGN opened at $13.36 on Friday. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -10.28 and a beta of 1.87. The business has a 50 day moving average of $17.70 and a 200 day moving average of $23.25. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. Myriad Genetics, Inc. has a 1-year low of $12.87 and a 1-year high of $29.30.

Insider Transactions at Myriad Genetics

In related news, CEO Paul J. Diaz sold 15,000 shares of Myriad Genetics stock in a transaction on Friday, October 11th. The shares were sold at an average price of $22.93, for a total value of $343,950.00. Following the transaction, the chief executive officer now owns 962,378 shares in the company, valued at $22,067,327.54. This trade represents a 1.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.10% of the company’s stock.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.